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| CASE SERIES DESCRIPTION
The first pregnancy occurred in a 27 year-old woman. She was diagnosed with afibrinogenemia at 7 years of age after a large hematoma formed on her buttocks and upper legs after playing on a seesaw, with a fibrinogen level <0.3 g/L. She had a homozygous nonsense mutation resulting in a STOP codon in the FGA gene (c.1001G > A, p.Trp334*). 10 Both parents were carriers of the mutation and had no history of abnormal bleeding or thrombosis. There was no consanguinity in the family. She was treated with on-demand fibrinogen concentrate from the time of diagnosis. During her first pregnancy, the patient planned a visit to the outpatient clinic to discuss her pregnancy. However, before the visit took place, she was admitted to the hospital at 13 weeks of pregnancy with subchorionic bleeding.
She received 2 g (33 mg/kg) of fibrinogen concentrate on admission followed by the continuous infusion of 4 g (67 mg/kg) of fibrinogen every 24 hours. However, 3 days after admission, ultrasound examination showed the loss of the fetal heartbeat, and a spontaneous miscarriage occurred. She had a dilation and curettage procedure in the operating room due to heavy blood loss. The total blood loss volume was 1100 cc and she received 2 units of packed red blood cells.
A year later, the patient became pregnant again, and prophylactic treatment with fibrinogen concentrate was started immediately, main- 
| DISCUSSION
These cases illustrate the difficulties faced when treating women with congenital afibrinogenemia, who experience an increased risk of both hemorrhage and thrombosis during pregnancy and in the peripartum period. Large-scale studies on this topic do not exist, but most guidelines, including the Dutch national guidelines, currently advise the maintenance of fibrinogen levels at ≥0.6 g/L during pregnancy F I G U R E 1 (A) Timeline of described pregnancies. Black = patient 1, white = patient 2, *in response to this, target fibrinogen levels were raised to ≥1.0 g/l for both patients, (B) Family tree. Grey = unconfirmed carrier Note: Patient numbers correspond to the associated number in the family tree in Figure 1B .
APTT, activated partial thromboplastin time; BAT, Bleeding Assessment Tool; NA: not available; PT, prothrombin time.
to prevent fetal loss; this level is based on expert opinion and case
